Evidence map›Paper›PMID 35875139›Full record

ReviewFrontiers in oncology2022

Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?

Liliana Montella, Nunzio Del Gaudio, Guglielmo Bove, Mariella Cuomo, Michela Buonaiuto, Davide Costabile, Roberta Visconti, Gaetano Facchini, Lucia Altucci, Lorenzo Chiariotti and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Liliana MontellaOncology Operative Unit, "Santa Maria delle Grazie" Hospital, ASL Napoli 2 NORD-, Pozzuoli, Italy.
Nunzio Del GaudioDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy.
Guglielmo BoveDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy.
Mariella CuomoCEINGE Biotecnologie Avanzate scarl, Napoli, Italy.
Michela BuonaiutoCEINGE Biotecnologie Avanzate scarl, Napoli, Italy.
Davide CostabileCEINGE Biotecnologie Avanzate scarl, Napoli, Italy.
Roberta ViscontiCEINGE Biotecnologie Avanzate scarl, Napoli, Italy.
Gaetano FacchiniOncology Operative Unit, "Santa Maria delle Grazie" Hospital, ASL Napoli 2 NORD-, Pozzuoli, Italy.
Lucia AltucciDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy.
Lorenzo ChiariottiCEINGE Biotecnologie Avanzate scarl, Napoli, Italy.
Rosa Della MonicaCEINGE Biotecnologie Avanzate scarl, Napoli, Italy.
Ceinge Biotecnologie Avanzate (Italy) · ITUniversity of Campania "Luigi Vanvitelli" · ITOspedale Santa Maria · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastomas are the most frequent and malignant brain tumor hallmarked by an invariably poor prognosis. They have been classically differentiated into primary isocitrate dehydrogenase 1 or 2 (

Indexed as

B-RafEGFRglioblastomaMetNF-1targeted therapy

Identifiers

PMID35875139
PMCPMC9306486
OpenAlexW4286630239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.